Which of the following medications—duloxetine 30 mg, lithium carbonate extended‑release 450 mg, doxepin 50 mg, tizanidine 4 mg, esomeprazole 40 mg, losartan with hydrochlorothiazide 25 mg, buprenorphine transdermal patch 10 µg/hr, scopolamine transdermal patch, potassium supplement, and magnesium supplement—are likely contributing to the patient’s idiopathic intracranial hypertension and should be discontinued?

Drug-Induced Idiopathic Intracranial Hypertension: Medication Review

Among this medication list, lithium is the most strongly associated with drug-induced intracranial hypertension (DIIH) and should be discontinued immediately if IIH is confirmed. 1

High-Risk Medications Requiring Discontinuation

Lithium (450 mg ER) - DISCONTINUE

• Lithium is classified as Category IV-V (strongly associated) with drug-induced intracranial hypertension based on systematic review of verifiable DIIH cases 1
• This represents the highest-risk medication on this list for causing or exacerbating IIH
• Discontinuation should be coordinated with the prescribing psychiatrist to manage withdrawal and transition to alternative mood stabilizers 1

Moderate-Risk Medications Requiring Evaluation

Doxepin (50 mg) - CONSIDER DISCONTINUATION

• Tricyclic antidepressants are specifically cautioned against in IIH management guidelines because they promote weight gain, which is the primary disease-modifying factor in IIH 2
• The 2018 consensus guidelines explicitly warn against selecting drugs that could increase weight, listing tricyclic antidepressants as problematic 2
• If doxepin is being used for depression or headache prophylaxis, transition to venlafaxine (weight-neutral and helpful with depression) or candesartan (useful for migraine prophylaxis without weight gain) 2

Duloxetine (30 mg) - CONTINUE WITH MONITORING

• Duloxetine is not listed among established DIIH-causing medications in the systematic review of drug-induced cases 1
• The FDA label does not identify intracranial hypertension as an adverse effect 3
• This medication can be safely continued as it does not contribute to weight gain and may help with comorbid pain or depression 3

Low-Risk Medications - CONTINUE

Tizanidine (4 mg)

• Not associated with DIIH in systematic reviews 1
• FDA labeling identifies cardiovascular effects (hypotension, bradycardia) and sedation as primary concerns, not intracranial pressure elevation 4
• Continue this medication as it does not contribute to IIH pathophysiology 4

Esomeprazole (40 mg)

• No association with DIIH identified in literature 1
• Continue for gastroprotection, particularly if patient is on multiple medications 1

Losartan-HCTZ

• Not associated with DIIH 1
• Losartan may actually be beneficial as an alternative to beta-blockers for migraine prophylaxis in IIH patients, given its lack of weight gain and depressive side effects 2
• Continue for hypertension management 2

Buprenorphine Patch (10 µg/hr)

• Not associated with DIIH 1, 5
• However, opioid medications should be gradually removed per IIH headache management guidelines, as medication overuse headache is common in IIH and prevents optimization of preventative treatments 2
• If used for chronic pain, consider transitioning to non-opioid alternatives over at least 1 month 2

Scopolamine Transdermal

• Not associated with DIIH 1
• Continue if needed for nausea or motion sickness 1

Potassium and Magnesium Supplements

• No association with DIIH 1
• Continue as indicated for electrolyte management, particularly if patient is on diuretics for IIH treatment 1

Critical Management Algorithm

1. Immediate action: Discontinue lithium with psychiatric consultation 1
2. Within 1-2 weeks: Taper doxepin and transition to weight-neutral alternative (venlafaxine or candesartan) 2
3. Ongoing: Initiate weight loss strategies as the only disease-modifying therapy for IIH 2
4. Monitor: Assess for medication overuse headache from buprenorphine and plan gradual opioid withdrawal if present 2
5. Continue: Duloxetine, tizanidine, esomeprazole, losartan-HCTZ, scopolamine, and supplements 3, 4, 1

Common Pitfalls to Avoid

• Do not abruptly discontinue lithium without psychiatric input, as this risks mood destabilization 1
• Do not overlook weight gain from tricyclic antidepressants (doxepin), as obesity is the primary modifiable risk factor in IIH 2
• Do not continue opioids long-term if medication overuse headache is present, as this prevents effective preventative treatment 2
• Do not assume all psychotropic medications worsen IIH—duloxetine and venlafaxine are weight-neutral options 2, 3